Showing results (501-510 of 513) with videos related to
Sort By:
Pageof 52
Cancer Research and Treatment|April 26, 2018
Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer PatientsSe-Hoon Lee, Boram Lee, Joon Ho Shim, et al.Nature Communications|November 11, 2017
Prevalence and detection of low-allele-fraction variants in clinical cancer samplesHyun-Tae Shin, Yoon-La Choi, Jae Won Yun, et al.Targeted Oncology|November 3, 2025
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON StudyRachel E Sanborn, Caicun Zhou, Ke-Jing Tang, et al.Nature|February 18, 2026
The integrated stress response promotes immune evasion through lipocalin 2Jozef P Bossowski, Ray Pillai, John Kilian, et al.European Journal of Cancer (Oxford, England : 1990)|July 29, 2025
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 studyMariam Alexander, Ying Cheng, Se-Hoon Lee, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2025
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort ABenjamin Besse, Koichi Goto, Yongsheng Wang, et al.Cancer Research and Treatment|July 8, 2016
Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in KoreaByung Sup Kim, Ho Jun Seol, Do-Hyun Nam, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2024
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 StudyNatasha B Leighl, Hiroaki Akamatsu, Sun Min Lim, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 5, 2020
New Approaches to SCLC Therapy: From the Laboratory to the ClinicJohn T Poirier, Julie George, Taofeek K Owonikoko, et al.Nature|April 12, 2023
Antibodies against endogenous retroviruses promote lung cancer immunotherapyKevin W Ng, Jesse Boumelha, Katey S S Enfield, et al.Pageof 52